4.4 Article

Percutaneous Mechanical Atherectomy Plus Thrombectomy Using the Rotarex®S Device Followed by a Drug-Coated Balloon for the Treatment of Femoropopliteal Artery In-stent Restenosis: A Prospective Single-Center, Single-Arm Efficacy Trial (PERMIT-ISR Trial)

Journal

FRONTIERS IN SURGERY
Volume 8, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fsurg.2021.671849

Keywords

peripheral arterial disease (PAD); femoropopliteal artery disease (FPA); in-stent restenosis (ISR); percutaneous mechanical atherectomy plus thrombectomy (PMAT); drug-coated balloon (DCB)

Categories

Funding

  1. Capital Health Research and Development of Special [2020-2-1102]
  2. National Natural Science Foundation of China [82000429]
  3. Beijing Municipal Administration of Hospitals Incubating Program [PX2021002]
  4. Scientific Research Program of Beijing Education Commission [KM202110025016]

Ask authors/readers for more resources

This study evaluated the safety and midterm outcomes of percutaneous mechanical atherectomy plus thrombectomy (MATH) using the Rotarex S catheter followed by a DCB in the treatment of femoropopliteal artery in-stent restenosis (ISR). The results showed high technical success rate and freedom from TLR at 1 year, with significant improvements in Rutherford category and ABI at the 12-month follow-up. Risk factors for TLR were identified as GLASS classification III and postoperative Rutherford classification >= 4.
Background: Studies investigating debulking devices with drug-coated balloons (DCBs) in the treatment of femoropopliteal (FP) artery in-stent restenosis (ISR) are limited. We aimed to evaluate the safety and midterm outcome of percutaneous mechanical atherectomy plus thrombectomy (MATH) using the Rotarex (R) S (Straub Medical, Wangs, Switzerland) catheter followed by a DCB in the treatment of FP-ISR. Methods: This study was a single-center single-arm trial. Patients with symptomatic (Rutherford category 2-5) de novo restenosis lesions of FP-ISR were treated with MATH and subsequent DCB. From June 2016 to May 2018, 59 patients with FP-ISR were enrolled. The primary endpoint was target lesion revascularization (TLR) and changes in the Rutherford category of the target limb at 12 months. Secondary endpoints included primary and secondary patency at 12 months, technical success rate, major adverse events, and ankle-brachial index (ABI). Risk factors for TLR were analyzed using Cox proportional hazard model. Results: The average follow-up time was 33 & PLUSMN; 8 months. The rate of technical success was 88.1% (52/59). Nine patients received bailout stenting. The rate of freedom from TLR was 84.7% (50/59) at 1 year, the Rutherford category changed at 12 months were significantly improved from baseline (p < 0.01). The primary patency rates and the secondary patency at the 12-month follow-ups were 82.5 and 92.5%, respectively. The ABI changed at 12 months were significantly improved from baseline (p < 0.01). Global limb anatomic staging system (GLASS) classification III [hazard ratio (HR) 18.44, 95% CI (1.57-215.99), p = 0.020] and postoperative Rutherford classification >= 4 [HR 8.28, 95% CI (1.85-37.06), p = 0.006] were identified as independent predictors of TLR. Conclusion: Our preliminary data suggested that MATH using a Rotarex (R) S catheter combined with DCB angioplasty is a safe, minimally invasive, and effective treatment for FP-ISR with favorable, immediate, and midterm outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available